Concentra Biosciences, LLC sent an unsolicited proposal to acquire Theseus Pharmaceuticals, Inc. (NasdaqGS:THRX) on November 24, 2023. As per consideration, Concentra Biosciences to acquire all outstanding shares of common stock of the Theseus Pharmaceuticals for $3.80 per share in cash, plus a contingent value right.
Theseus Pharmaceuticals, Inc.
Equities
THRX
US88369M1018
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+8.63% | 114B | |
+13.17% | 107B | |
-12.76% | 22.22B | |
-2.24% | 21.28B | |
-7.19% | 17.51B | |
-39.93% | 17.17B | |
+6.67% | 14.14B | |
+33.90% | 12.2B | |
-28.60% | 7.83B |